Overview and Scope
Gaucher’s disease is a rare genetic disorder that interferes with the metabolism of a particular kind of fat called glucocerebroside. This disorder is caused by the formation of a fatty substance called glucocerebroside within certain cells, particularly in the spleen, liver, bone marrow, and sometimes in the brain.
Sizing and Forecast
The gaucher’s disease market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.68 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to enzyme replacement therapy (ert) development, increasing disease awareness, genetic research and diagnosis, patient advocacy initiatives, government incentives for rare diseases.
The gaucher’s disease market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to next-generation therapies, global patient registry expansion, improvements in access to treatment, personalized medicine approaches, regulatory support for rare diseases. Major trends in the forecast period include technological innovations in treatment monitoring, international collaborations in research, oral therapeutics advancements, expanded newborn screening programs, global collaboration for patient access.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report
Segmentation & Regional Insights
The gaucher’s disease market covered in this report is segmented –
1) By Type: Gaucher Disease Type 1, Gaucher Disease Type 2, Gaucher Disease Type 3, Other Types
2) By Diagnosis: Physical Exam, Blood Tests, Imaging Tests, Preconception Screening and Prenatal Testing, Other Diagnoses
3) By Therapy: Enzyme Replacement Therapy, Substrate Reduction Therapy
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End User: Hospitals, Specialty Clinics, Homecare, Other End Users
North America was the largest region in the Gaucher’s disease market in 2023. Europe is expected to be the fastest growing region in the forecast period. The regions covered in the gaucher’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13241&type=smp
Major Driver Impacting Market Growth
The rising prevalence of genetic abnormalities is expected to propel the growth of the Gaucher’s disease market going forward. Genetic abnormalities are changes or mutations that occur in the DNA sequence of a person’s genes and may result in abnormal features, functions, or characteristics. The inheritance pattern of Gaucher’s disease is autosomal recessive, which means that an individual must inherit two copies of the mutated GBA gene, one from each parent, to develop the disease. People with Gaucher’s disease do not make enough of this enzyme, which leads to a buildup of fatty substances called lipids in certain organs such as the spleen and liver. For instance, in May 2021 according to MedlinePlus’s report, a US-based online information service provider by the United States National Library of Medicine, syndrome A is identified in about 1 in 200,000 Americans each year and currently around 100,000 kids suffer from syndrome B, whereas, it is estimated nearly 12,000 people died globally from syndrome C in the year 2020 and approximately 1% of people in the United States develop disorder D during their lifetimes. Therefore, the rising prevalence of genetic abnormalities is driving the growth of the Gaucher’s disease market.
Key Industry Players
Major companies operating in the gaucher’s disease market report are Pfizer Inc., Johnson & Johnson, Merck and Co. Inc., Novartis AG, Sanofi S.A., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Moderna Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, BioMarin Pharmaceutical Inc., CHIESI Farmaceutici SPA, IntraBio Inc., REGENXBIO Inc., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Pharming Group N.V., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, AVROBIO Inc., Resverlogix Corp., GenSight Biologics S.A., ISU Abxis Co. Ltd., SIRION BIOTECH GmbH, Greenovation Biotech GmbH, Orphazyme A/S
The gaucher’s disease market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
